B
Berry Genomics / 贝瑞基因
Beijing SZSE-listed clinical genomics / NIPT OEM (000710)
About Berry Genomics / 贝瑞基因
Beijing SZSE-listed clinical genomics OEM (Berry Genomics / 贝瑞基因; SZSE 000710) offering NIPT, hereditary-disease WES/CNV-seq, research sequencing services and oncology adjacency. Founded in May 2010 with Beijing Changping Life Science Park HQ narrative and labs in Beijing/Qingdao/Fuzhou plus Hangzhou·Fuzhou reagent/instrument plants. Serves hospitals and clinical channels across the prenatal-to-oncology continuum as a mid-size China NGS leftover peer beyond GeneCast, Basecare and Burning Rock; not a Dongcheng District-only pin.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2010
- Headquarters
- China
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
66 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Berry Genomics / 贝瑞基因 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Berry Genomics / 贝瑞基因 on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.